Mark Iwicki

Mark Iwicki serves as Board Chair for Q32 Bio Inc., Third Harmonic Bio, Akero Therapeutics, and Aerovate Therapeutics, Inc. Mark is a Director at Merus and Nimbus Therapeutics, and previously held director roles at Pulmatrix Inc., Aimmune Therapeutics, and Taris Biomedical. In addition to these positions, Mark Iwicki is the Chairman and CEO of Kala Pharmaceuticals. Mark Iwicki earned a Master of Business Administration with a focus on Marketing and Finance from Loyola University Maryland and a Bachelor of Science in Business Administration and Management from Ball State University.